With its own diagnostic code, non-radiographic axial spondyloarthritis may become easier to diagnose and study over time.
Many people do not suspect arthritis as a cause of their back pain, even though arthritis in the back is very common.
While many studies have shown these medications help treat AS symptoms, more research has been needed about their impact on long-term disease progression.
‘I’ve got no idea how to use pain scales to record different kinds of pain … from different sources … and at different times and intensities.’
‘Identification, evaluation, and management of enthesitis is critical to ameliorate the overall burden of disease,’ according to researchers.
“An improved risk stratification and vigilance for early diagnosis and treatment of AS particularly in African American patients is needed,” say study authors.
Cosentyx is the second interleukin-17 drug approved for non-radiographic axial spondyloarthritis, which is adding to treatment options for patients with this type of inflammatory arthritis.
This research confirms the important role of high-intensity exercise in the treatment of axSpA, say study authors.
Could pain symptoms be improved in researchers assess patients’ pain perception as part of their treatment plan?
In a new study, hardly anyone who had nr-axSpA at baseline developed spinal damage within two years.